Infectious Disease Research Institute
IDRI was founded in 1993.
IDRI is collaborating with the United States Agency for International Development to develop a malaria vaccine with the Walter Reed Army Institute of Research using Walter Reed's CelTOS malaria antigen in conjunction with IDRI's GLA-SE adjuvant.
Visceral leishmaniasis vaccine
On February 2012, IDRI launched the world’s first clinical trial of the visceral leishmaniasis vaccine. The vaccine is a recombinant form of two fused Leishmania parasite proteins with an adjuvant. Two phase 1 clinical trials with healthy volunteers are to be conducted. The first one takes place in Washington and is followed by a trial in India. The trials are funded by the Bill & Melinda Gates Foundation.
- Erica Teichert (18 August 2011). "USAID, IDRI form malaria vax collaboration". fiercevaccines.com. Retrieved 12 September 2011.
- Elvidge, Suzanne (February 23, 2012). "World’s first kala azar vaccine enters the clinic". FierceVaccines.com. Retrieved March 1, 2012.